PrognomiQ
Bruce Wilcox is the Chief Technology Officer of PrognomiQ. Previously, he was Chief Executive Officer and Founder of DiscernDx. Prior to this, he was Senior Vice President, Research and Development for Applied Proteomics, where he developed and launched the SimpliPro Colon test, a proteomic blood-based test for colon cancer. Earlier in his career, Bruce had multiple R&D leadership roles at Applied Minds, Eksigent Technologies, Nanostream, and Hamilton Sundstrand Sensor Systems, where he supported the development and commercialization of mass spectrometry instruments and systems in multiple applications. Bruce received his Ph.D. in Analytical Chemistry from the University of New Mexico, and his B.S. in Chemistry from North Dakota State University.
This person is not in any offices
PrognomiQ
1 followers
PrognomiQ aims to generate proteomic information with high accuracy, scale and speed. This proteomic data will be complemented with genomic, metabolomic and other health information to deliver first-in-class test products that enable early disease detection and treatment.